Biogen(US:BIIB) ZACKSยท2025-04-30 14:21Core Viewpoint - Analysts forecast a decline in Biogen Inc.'s quarterly earnings and revenues, indicating potential challenges for the company in the upcoming earnings report [1]. Earnings and Revenue Estimates - Biogen is expected to report earnings of $3.32 per share, reflecting a year-over-year decline of 9.5% [1]. - Revenue is anticipated to be $2.23 billion, showing a decrease of 2.6% compared to the same quarter last year [1]. - Over the past 30 days, the consensus EPS estimate has been adjusted upward by 0.1%, indicating a slight positive reassessment by analysts [2]. Product-Specific Revenue Estimates - Revenue from Multiple Sclerosis (MS) product TYSABRI is estimated at $364.47 million, down 15.5% year-over-year [5]. - Revenue from Rare Disease product SPINRAZA is projected at $365.01 million, up 7% year-over-year [5]. - Total net revenue from products is expected to reach $1.66 billion, reflecting a decline of 3% from the previous year [6]. - Revenue from Anti-CD20 therapeutic programs is estimated at $411.57 million, indicating a growth of 4.5% year-over-year [6]. Regional Revenue Estimates - Revenue from MS product TYSABRI in the United States is forecasted at $191.97 million, down 10.2% year-over-year [9]. - Revenue from MS product Fumarate (TECFIDERA) in the United States is expected to be $31.40 million, reflecting a significant decline of 28.1% [9]. - Revenue from SPINRAZA in the United States is projected at $160.72 million, up 8.2% year-over-year [7]. - Revenue from MS product Interferon in the United States is expected to be $119.70 million, down 14.4% year-over-year [10]. Market Performance - Over the past month, Biogen shares have decreased by 9%, contrasting with the Zacks S&P 500 composite's slight decline of 0.2% [10]. - Biogen holds a Zacks Rank of 3 (Hold), suggesting that its performance may align with the overall market in the near term [10].